Namyang Dairy is in trouble after a number of furious investors have called for a boycott. They urged the consumers to stop buying the company’s products.
Namyang’s COVID-19 claim
The root cause of this action from the investors was Namyang Dairy’s claim that its Bulgaris yogurt drink can help fight the symptoms of COVID-19. Last week, the South Korean food and dairy company said that its stock price increased by more than eight percent on April 13 and continued to go up to over 28% the next day.
At that time, it was reported that Namyang’s share surge was caused by the consumers’ rush to buy its Bulgaris yogurt after it released a statement saying that the product can prevent COVID-19. However, health officials are questioning the company’s claims and suggested that they are false and have no scientific basis.
The controversial claim was announced during a symposium hosted by the Korea Research & Institute of BioMedical last week. At the event, Namyang’s internal research institute presented the results of its research on Yogurt drink called Bulgaris, as per The Korea Herald.
“We’re the first firm in the country that has discovered fermented dairy products are effective in preventing influenza and COVID-19 viruses,” Company’s representative, Park Jong Su, said at the symposium. “Our experiments showed that Bulgaris helped remove the influenza A (H1N1) virus at a 99.999 percent rate of success, and the COVID-19 at a 77.8 percent success rate.”
S. Korea’s food and drug ministry reacts
The experts from the Ministry of Food and Drug Safety and Korea Disease Control and Prevention Agency immediately questioned Namyang’s statements about its Bulgaris yogurt. They are asking about the effectiveness claim against COVID-19 and they concluded that the dairy firm exaggerated the research results that it released in the previous symposium.
The Korea Times reported that because of this, the investors are now taking action against Namyang. They are using social media to ask the public to join in their calls to boycott the company’s products. Apparently, they are angry not just due to the coronavirus statements but also because they believe Namyang lied to manipulate the stock price.
Meanwhile, amid the backlash from the public and health experts, Namyang Dairy issued an apology for the confusion. "We apologize to our customers for causing misunderstanding with our research results,” a company official stated. “The test was not based on human testing, but at the cellular stage, from which we couldn't have concluded its effectiveness against COVID-19."


Gold Prices Steady as Hormuz Tensions Fuel Fed Rate Concerns
US Dollar Falls as Weak July Jobs Report Dents Fed Rate Hike Bets
DBS Raises 2025 Outlook After Record Q2 Profit Driven by Wealth Management
Oil Prices Set for Steep Weekly Losses as Hormuz Deal Stalls
Asian Currencies Hold Steady as US Dollar Nears Seven-Week Low Ahead of Key Jobs Data
China Exports Beat July Forecasts as AI Demand Fuels High-Tech Trade
Singapore Says One-Third of U.S. Exports Hit by New 12.5% Tariff
Gold Price Hits Seven-Week High as Fed Rate Hike Bets Fade and Hormuz Deal Hopes Grow
Canada, US Hold Constructive Trade Talks as Tariff Negotiations Continue
Trump Unveils $3 Billion U.S. Critical Minerals Push
US Job Growth Seen Picking Up in July
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+
DeepSeek to Raise AI API Prices as Demand for New Models Surges
Berkshire Hathaway Cash Falls as Abel Boosts Stock Buybacks
Nvidia to Invest Up to $3 Billion in Blackstone-Backed Lancium
Siemens Energy Q3 Profit Beats Forecast as AI-Driven Power Demand Fuels Growth
SoftBank Q1 Profit Beats Forecast as Intel Rally and OpenAI Investments Boost Returns 



